The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients |
| |
| Institution: | 1. Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, No.42, Baiziting, Nanjing City 210009, Jiangsu Province, China;2. Department of Hematology, The First Affiliated Hospital of Wannan Medical College, No.2, Zheshan West Road, Wuhu City 241001, Anhui Province, China;3. Department of Pathology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, No.42, Baiziting, Nanjing City 210009, Jiangsu Province, China;4. Soochow University, No.1, Shizi Street, Suzhou city 215006, Jiangsu Province, China;5. Clinic laboratory of Institute of Dermatology and Hospital for Skin Diseases, Chinese Academy of Medical Sciences, No.12, Jiangwangmiao Street, Xuanwu District, Nanjing City 210042, Jiangsu Province, China;6. Department of Radiotherapy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, No.42, Baiziting, Nanjing City 210009, Jiangsu Province, China;7. Department of Medical Oncology, Nantong Tumor Hospital, No.48, Qingnian West Road, Nantong city 226000, Jiangsu Province, China;8. Department of Medical Oncology, Lanxi County People''s Hospital. No.65, North Street of Langxi County, 242100, Anhui Province, China;1. School of Biological Sciences, University of Canterbury, Christchurch 8140, New Zealand;2. Department of Orthopaedic Surgery & Musculoskeletal Medicine, University of Otago Christchurch, PO Box 4345, Christchurch, New Zealand;3. Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch, New Zealand;4. Department of Radiology, University of Otago Christchurch, PO Box 4345, Christchurch 8011, New Zealand;1. Department of Pathology/Microbiology, University of Nebraska Medical Center, Omaha, NE, United States;2. Department of Internal Medicine, Division Diabetes, Endocrinology, and Metabolism, University of Nebraska Medical Center, Omaha, NE, United States;3. Department of Internal Medicine, Division of Endocrinology, Metabolism, and Genetics, University of Kansas Medical Center, Kansas City, KS, United States;4. Department of Pediatrics, Division of Clinical Genetics Children''s Mercy Kansas City, Kansas City, MO, United States;1. Department of Medicine, Stavanger University Hospital, Stavanger, Norway;2. Department of Natural Sciences, University of Agder, Kristiansand, Norway;3. Department of Medicine, Haukeland University Hospital, Bergen, Norway;4. Department of Medical Biochemistry, Stavanger University Hospital, Stavanger, Norway;1. UCIBIO\\REQUIMTE, Porto; CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Gandra-Paredes, Portugal;2. iCBR, Instituto de Investigação Clínica e Biomédica de Coimbra, Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal;3. Departamento de Ciências Biológicas, Laboratório de Bioquímica, Faculdade de Farmácia da Universidade do Porto (FFUP), Porto, Portugal;4. Instituto Politécnico de Coimbra, Escola Superior de Tecnologia da Saúde de Coimbra, Coimbra, Portugal;5. Hospital da Prelada-Dr. Domingos Braga da Cruz, Porto, Portugal;6. UCIBIO\\REQUIMTE, Departamento de Ciências Biológicas, Laboratório de Bioquímica, Faculdade de Farmácia da Universidade do Porto (FFUP), Porto, Portugal;7. Centro de Investigação em Ciências Saúde (CICS), Universidade da Beira Interior, Covilhã, Portugal |
| |
| Abstract: | ObjectiveTo evaluate cell-free DNA (cfDNA) in plasma as a promising biomarker for lymphoma, altered levels of cfDNA and its association with clinical parameters are investigated in patients suffered from lymphomas.MethodsPeripheral blood specimens were collected from 60 patients with lymphoma during initial diagnosis and those of another 107 patients with lymphoma during treated stage were also collected, 93 healthy volunteers were selected as control group. Quantitative PCR was used to detect cfDNA level in each group, cfDNA level in different groups was analyzed to understand its relationship with lymphoma patients' clinical features. After correlation analysis between cfDNA and clinical characteristics, Receiver operator characteristic curve was performed to analyze sensitivity and specificity of cfDNA and LDH.ResultscfDNA concentration and integrity in initial stage of lymphoma patients were significantly higher than those in treated stage, and cfDNA concentration in treated phase was significantly higher than cfDNA concentration in control group. There was no significant difference in cfDNA integrity at treated stage compared with control group. There was no significant correlation between patient's age, gender, extranodal invasion and lymphoma pathological type and cfDNA concentration and integrity; In contrast, there was a significant correlation between ECOG score, LDH content, Ann Arbor stage, IPI, B-symptoms, Ki-67 expression and radiotherapy and cfDNA concentration and integrity, both at the time of initial diagnosis and treated stage. cfDNA concentration detection is an optimal diagnostic indicator, followed by cfDNA integrity detection, the sensitivity and specificity of both are superior to the traditional LDH detection.ConclusioncfDNA level is significantly increased in lymphomas patient plasma and may help lymphoma screening. cfDNA level may serve as a potential indicator of lymphomas treatment efficacy. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
